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BACKGROUND. The number of mitoses and, thus, the proliferative capacity of a tumor
is one of the most crucial variables for tumor grading. The Ki-67 nuclear antigen may
be considered as an alternative to mitotic counts in grading schemes and as a single
parameter that can be used in fine-needle aspirates and small biopsies.
METHODS. Immunohistochemistry using the anti-Ki-67 antibody MIB-1 was per-
formed on 434 breast carcinoma specimens from the International Breast Cancer
Study Group (formerly Ludwig) Trial V. Three groups based on Ki-67 percent were
used to replace the mitotic counts component in the Nottingham grade (NHG) to
produce the Nottingham/Ki-67 grade (NKG) and to assess Ki-67 as a single parameter.
RESULTS. In both the lymph node positive subgroup and the lymph node negative
subgroup, the NKG and Ki-67 group was correlated significantly with Bloom–
Richardson grade (BRG), NHG, and Nottingham type. Tumor size in the lymph
node negative cohort and estrogen receptor status, progesterone receptor status,
and c-erbB-2 expression in the lymph node positive cohort also were correlated
significantly with NKG. Ki-67 percentage was correlated significantly with c-erbB-2
expression in the lymph node positive cohort only. NKG was similar to BRG and
NHG when it was evaluated for prognostic significance. Patients with higher
categoric Ki-67 percentages had worse overall and disease free survival in all
groups except for the untreated, lymph node negative group.
CONCLUSIONS. Ki-67 detection represents a valuable tool and is a good objective
substitute for mitotic counts when used in a grading system. When it is used alone,
Ki-67 detection provides valuable information, although it is necessary to combine
this with other parameters in the study of core biopsies and fine-needle aspirates.
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Because human breast carcinomas are known toexhibit a broad spectrum of clinical behavior,
many attempts have been made in the past to estab-
lish reliable and reproducible prognostic parameters.
Most commonly, morphologic criteria were used for
this purpose, such as the widely accepted tumor grad-
ing method according to Bloom–Richardson.1 Histo-
logic grade provides an overview of a number of mo-
lecular events that are reflected in morphology.1– 6
Three major elements are included in histologic grad-
ing: nuclear morphology (nuclear pleomorphism), dif-
ferentiation (tubule formation), and proliferation (mi-
totic frequency). Although methods for histologic
grading in patients with breast carcinoma were de-
scribed first over 100 years ago, a lack of precision in
the assessment of all three of the factors above men-
tioned resulted in a considerable element of subjec-
tivity and lack of reproducibility. Attempts to establish
more objective criteria of tumor differentiation and
proliferation were made. One of those attempts re-
sulted in the revised Nottingham grading method,7
which involves the semiquantitative evaluation of the
percentage of tubule formation, the degree of nuclear
pleomorphism, and mitotic counting in a defined field
area at a specific magnification. A numeric scoring
system is used, and the overall grade is derived from a
summation of individual scores for the three variables.
This method has now been accepted in the United
Kingdom as the national standard for grading and has
been proposed as a scheme to be adopted in Europe
and the United States.8 Tumor type adds independent
prognostic information, and tumors may be grouped
into four types based on prognosis.9
Just at the time when pathologists are beginning to
agree on criteria for the histologic assessment of primary
tumors, the clinical management of patients with breast
carcinoma is undergoing major changes. Many centers
in Europe and the United States currently are carrying
out trials of primary chemotherapy,10–12 and the results
indicate that this enables an improved cosmesis due to
tumor down-staging,13 with no apparent reduction in
disease free survival (DFS).10 Data indicate that exami-
nation of the sentinel lymph node is an important alter-
native to axillary dissection.14,15 Thus, although tumor
grading,7,8 vascular invasion,16 tumor size,17,18 and
lymph node involvement are accepted as the most im-
portant prognostic factors, the advent of primary che-
motherapy10–12 after diagnosis on a core biopsy is forc-
ing a reconsideration of how the pathologist can aid the
clinician based on the small samples, in which grading,
size, and lymph node involvement are no longer param-
eters that can be assessed.6,19 It is essential that studies
are carried out rapidly that assess the value of markers
that can be applied to small samples. Proliferation is an
obvious parameter for assessment.
For many years, cellular proliferation has been
measured by the numeration of mitotic figures in tis-
sue sections prepared for routine histomorphologic
studies. This method includes the inherent inability to
distinguish very condensed mitotic figures from pyc-
notic nuclei. Other techniques have been reported
that permit the evaluation of proliferative activity and
growth fraction of tumors.20,21 Monoclonal antibodies
to different proliferating cell nuclear antigens have
been described,22,23 including Ki-67.24,25 Ki-67 antigen
is a nonhistone protein that was described in 1983 and
is expressed in cycling cells in G1 phase, S phase, G2
phase, and during mitosis, but not in G0 phase, allow-
ing estimation of the growth fraction after a relatively
small number of cells have been counted. Thus, in a
true-cut biopsy or fine-needle aspirate (FNA), infor-
mation can be obtained about the growth fraction,26
although insufficient cells would be available to carry
out a routine count. Most studies have been per-
formed on frozen sections; however, the anti-Ki-67,
MIB-1 antibody also is applicable on routinely fixed,
paraffin embedded tissues after microwave pretreat-
ment.27 Published data have shown a good correlation
of the immunoreactivity with DNA cytometry and bro-
modeoxyuridine.28 –31 MIB-1 appears to be superior to
other antibodies for assessing cycling cells on rou-
tinely fixed and processed material, not only because
of the simplicity of the technique, but because good
correlation with Ki-67 expression on frozen material
has also been reported.32 Many studies have assessed
the association between Ki-67 immunoreactivity with
other prognostic factors in breast carcinomas. How-
ever, few studies have assessed the percentage of tu-
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mor cells that express the Ki-67 antigen from patients
with long-term follow-up because of the difficulty in
obtaining sufficient archival frozen tissue.
In this study, we assessed the information gained
from carrying out a Ki-67 assessment relative to other
parameters that we studied previously in a well-de-
fined data set available to us through the International
Breast Cancer Study Group (IBCSG).33–39 The objec-
tives of the current study were 1) to analyze Ki-67 as a
substitute for mitotic counting in the Nottingham
grade (NHG) system to produce a Nottingham/Ki-67
grade (NKG), thus giving an indication of the value of
this measure of growth fraction compared with mi-
totic counts; and 2) to assess the value of Ki-67 as an
individual marker of prognosis and treatment re-
sponse of patients with breast carcinoma against
grade and other factors in the data base.
MATERIALS AND METHODS
Trial Design
The material used in this study was from a cohort of
patients who were enrolled into the (IBCSG) Ludwig
Trial V.33–35 From 1981 to 1985, the IBCSG (formerly
the Ludwig Breast Cancer Study Group) conducted a
randomized clinical study to assess the effect of early
commencement of adjuvant cyclophosphamide,
methotrexate, and 5-fluorouracil (CMF) chemother-
apy in patients with lymph node negative and lymph
node positive breast carcinoma. Of 2504 eligible pa-
tients, 1275 patients with lymph node negative breast
carcinoma were randomized to receive either a single
cycle of perioperative chemotherapy (PeCT) or no ad-
juvant chemotherapy. Patients with lymph node pos-
itive disease (n  1229 patients) were assigned to one
of three treatments: PeCT, a conventionally timed
chemotherapy regimen, or both. The PeCT regimen
was a combination of intravenous CMF given on Days
1 and 8 and commencing within 36 hours of mastec-
tomy. The conventionally timed chemotherapy regi-
men was CMF (cyclophosphamide was given orally)
plus low-dose, continuous prednisone starting 25–36
days after mastectomy and continuing for 6 cycles
every 28 days. Postmenopausal patients with lymph
node positive breast carcinoma who were assigned to
receive the conventionally timed chemotherapy regi-
men also received tamoxifen for 6 months. The trial
and the clinical results have been described in detail
elsewhere.33–35
Study Cohort
In 1993, the IBCSG established a tissue bank of tumor
blocks from a subset of Trial V patients. These patho-
logic parameters then were merged with the clinical
data base that was begun in 1981 and is updated
annually for survival and disease status.
The Ki-67 study samples consisted of formalin
fixed, paraffin embedded tissue sections that were
available from 494 patients from 4 IBCSG member
institutions (Ljubljana, Madrid, Perth, and Brescia). A
total of 434 patients with ascertainable Ki-67 percent-
age, Bloom–Richardson grade (BRG), NHG, and Not-
tingham type were available for final statistical analy-
sis. BRG, vessel invasion, and pathologic tumor size
were available from previous central pathology review.
The Nottingham grading was carried out by the Not-
tingham Group, as described previously.39 Sections
were excluded on the basis of absence of invasive
tumor in the material available and lack of any posi-
tive staining in the sections. The latter was used to
exclude material, because it was possible that the ab-
sence of staining was a reflection of the fixation of the
material. Thus, some positive nuclei were required for
an internal quality control for the section.
These 434 patients reflected the overall trial pop-
ulation as closely as possible with respect to meno-
pausal status, treatment, tumor size, and estrogen re-
ceptor (ER) status. Of 434 patients in the study, 188
patients had no histologic evidence of disease in the
lymph nodes, and 246 patients had metastatic disease
in the axilla. Sixty-three patients with lymph node
negative disease were randomized to receive no adju-
vant treatment, and 125 patients with lymph node
negative disease were randomized to receive PeCT.
Among the patients with lymph node positive disease,
89 patients were randomized to receive PeCT, and 157
were randomized to receive prolonged treatment (6 or
7 cycles). The median follow-up for the Ki-67 study
group was 13.5 years at the time of this analysis.
Immunohistochemical Labeling and Tissue Evaluation
Staining was performed with the MIB-1 monoclonal
antibody. The antibody was obtained from Immuno-
tech International and was supplied to them by The
Binding Site Limited (Institute of Research and Devel-
opment, Birmingham, United Kingdom). Staining was
performed using the indirect immunoperoxidase avi-
din-biotin-complex (ABC) technique. Paraffin embed-
ded tissue sections, 3 M thick, were deparaffinized in
xylene, rehydrated through graded alcohols, and
blocked for endogenous peroxidase activity with hy-
drogen peroxidase. They were then microwaved on
full power for 10 minutes in 1 L of citrate buffer. The
microwave used was a Proline Micro Chef (model
ST44; 950 Watts). After cooling by running under cold
water and blocking for nonspecific activity with rabbit
serum, the sections were incubated with the mono-
clonal antibody MIB-1 at a 1:50 dilution for 2 hours.
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The detection system used a biotinylated rabbit anti-
mouse polyclonal serum (catalog no. E0354; Dako,
Glostrup, Denmark) at 1:200 dilution, followed by
strepavidin-ABC/horseradish peroxidase (catalog no.
K0377; Dako) according to the manufacturer’s instruc-
tions.
The slides were examined and scored by one ob-
server (H.T.) who was blinded to both clinical data and
pathologic data. Ki-67 expression was quantified using
a visual grading system. The percentage of Ki-67 pos-
itive cells among the total number of total counted
neoplastic cells was determined at a magnification of
 400 using an eye-piece graticule and counting 10
randomly selected fields. All tumor cells were counted,
and the number of nuclei counted ranged from 638 to
7871.
Statistical Analysis
Three ordered categories of Ki-67 were created based
on the percentage of Ki-67 positive nuclei:  9.5%,
 9.5% and  15.5%, and  15.5%. The selection of
these cut-off values was based on the proportion of
tumors that scored 1 point, 2 points, and 3 points of
mitotic activity using the criteria of Elston and Ellis.7
The agreement between the Ki-67 categories and the
mitotic count scores was high, with a  interrater
agreement score40 of 74%, in which a perfect match
was considered perfect agreement, and a difference
between adjacent categories was considered partial
agreement. The observed agreement between these
two measures of cell proliferation was significantly
higher than chance alone would indicate (P  0.0001).
These ordered categories of Ki-67 were then
scored 1–3, with increasing scores indicating higher
Ki-67 percentages and were used in place of the mi-
totic counts feature in the NHG system. The resulting
adjusted Nottingham grade, hereafter referred to as
Nottingham/Ki-67 grade (NKG), was then studied sep-
arately for the lymph node negative subgroup (n 188
patients) and the lymph node positive subgroup (n
 246 patients). Pearson chi-square statistics were
used to study associations between patient character-
istics, the newly created Ki-67 percent categories, and
the NKG according to lymph node status.41 The 
statistic was used to correlate the NKG with existing
BRG and NHG.
The Nottingham type categorizes tumors into four
groups based on histology and prognosis.9 Tumors
that indicate an excellent prognosis (80% 10-year sur-
vival rate) include tubular, invasive cribiform, muci-
nous, and tubulolobular carcinomas. Tumors that in-
dicate a good prognosis (60 – 80% 10-year survival rate)
include tubular mixed, mixed ductal with special type,
and alveolar lobular carcinomas. Invasive papillary,
classical lobular, medullary, and atypical medullary
carcinomas overall indicate a moderate prognosis
(50 – 60% 10-year survival rate); and ductal (no special
type), solid lobular, mixed ductal with lobular, and
lobular mixed carcinomas indicate a poor prognosis
( 50% 10-year survival rate).9
DFS was defined as the time from randomization
to recurrence, metastasis, appearance of a second pri-
mary tumor, or death from any cause, whichever oc-
curred first. Overall survival (OS) was defined as the
time from randomization to death from any cause.
Univariate and multivariate hazard ratios (HRs) corre-
sponding to DFS and OS, 95% confidence intervals
(95%CIs) for these HRs, and associated P values were
calculated using Cox proportional hazards regression
models according to lymph node status group.42
Kaplan–Meier estimates for DFS and OS, stratified by
lymph node status and NKG, were used in plots and in
10-year survival estimates.43
RESULTS
Ki-67 As an Alternative to Mitotic Count in the NHG
System
Significant associations between the NKG, NHG, and
BRG systems were observed (P  0.001) in both the
lymph node positive cohort and the lymph node neg-
ative cohort (Table 1). Agreement between the three
systems was high, with  statistics of 88% between
NKG and NHG and 80% between NKG and BRG, in
which partial agreement between grading systems was
credited for patients assigned to adjacent grades in the
different systems. The observed agreement between
any two grading systems was significantly higher than
chance alone would indicate. Overall, the NKG cate-
gorized 18%, 50%, and 32% of patients with lymph
node negative disease and 11%, 55%, and 33% of pa-
tients with lymph node positive disease as Grades 1, 2,
and 3, respectively. Among patients with lymph node
negative disease, the classification of tumors as Grade
1 by the NHG and NKG systems included more lesions
of BRG 2 and BRG 3 (overall, 33 tumors and 36 tumors
were classified as NKG 1 and NHG 1, respectively,
compared with 21 tumors that were classified as BRG
1). The number of tumors classified as Grade 1 among
patients with lymph node positive disease was similar:
NKG 1, 28 tumors (11%); NHG 1, 26 tumors (10.5%);
and BRG 1, 26 tumors (10.5%). Conversely, the BRG 3
category included a greater proportion of tumors
compared with the NKG 3 and NHG 3 categories
among both patients with lymph node negative dis-
ease and patients with lymph node positive disease.
Associations between the NKG and patient char-
acteristics were assessed for patients with lymph node
negative disease and patients with lymph node posi-
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TABLE 1
Correlations between Nottingham/Ki-67 Grade and Other Patient Characteristics According to Lymph Node Status
Characteristic
Nottingham/Ki-67 grade (%)
P value
(chi-square test)aGrade 1 Grade 2 Grade 3
Lymph node negative 33 (18) 94 (50) 61 (32) —
Bloom–Richardson grade
1 14 (67) 6 (29) 1 (5) —
2 17 (20) 55 (65) 13 (15)  0.001 ( 0.001,  0.001)
3 2 (2) 33 (40) 47 (57) —
Nottingham grade
1 33 (92) 3 (8) 0 (0) —
2 0 (0) 69 (78) 19 (22)  0.001 ( 0.001,  0.001)
3 0 (0) 22 (34) 42 (66) —
Pathologic tumor size (cm)
 2 22 (26) 40 (48) 22 (26) —
 2 10 (10) 50 (51) 39 (39) 0.02 (0.001, 0.001)
Unknown 1 (20) 4 (80) 0 (0) —
ER status
Negative (0–9 fmol) 15 (21) 32 (44) 25 (35) —
Positive ( 10 fmol) 15 (16) 51 (54) 29 (31) 0.79 (0.08, 0.21)
Unknown 3 (14) 11 (52) 7 (33) —
PgR status
Negative (0–9 fmol) 12 (14) 41 (48) 32 (38) —
Positive ( 10 fmol) 12 (20) 30 (50) 18 (30) 0.62 (0.02, 0.005)
Unknown 9 (21) 23 (53) 11 (26) —
Vessel invasion by primary tumor
No 20 (21) 46 (48) 30 (31) 0.30 (0.23, 0.04)
Yes 12 (13) 48 (54) 29 (33) —
Unknown 1 (33) 0 (0) 2 (67) —
c-erbB-2
Negative 33 (20) 84 (50) 50 (30) 0.07 (0.08, 0.11)
Positive 0 (0) 10 (53) 9 (47) —
Thymidylate synthase
Low 7 (14) 26 (51) 18 (35) —
High 26 (19) 67 (49) 43 (32) 0.77 (0.60, 0.74)
Unknown 0 (0) 1 (100) 0 (0) —
Nottingham type by prognosis category
1. Excellent 4 (100) 0 (0) 0 (0) —
2. Good 23 (66) 10 (29) 2 (6)  0.001 ( 0.001,  0.001)
3. Average 0 (0) 15 (83) 3 (17) —
4. Relatively poor 6 (5) 69 (53) 56 (43) —
Lymph node positive 28 (11) 136 (55) 82 (33) —
Bloom–Richardson grade
1 15 (58) 11 (42) 0 (0) —
2 12 (12) 70 (69) 20 (20)  0.001 ( 0.001,  0.001)
3 1 (1) 55 (47) 62 (53) —
Nottingham grade
1 25 (96) 1 (4) 0 (0) —
2 3 (2) 107 (79) 25 (19)  0.001 ( 0.001,  0.001)
3 0 (0) 28 (33) 57 (67) —
Pathologic tumor size (cm)
 2 15 (19) 41 (53) 22 (28) —
 2 12 (7) 93 (57) 57 (35) 0.07 (0.03, 0.02)
Unknown 1 (17) 2 (33) 3 (50) —
ER status
Negative (0–9 fmol) 6 (7) 40 (47) 40 (47) —
Positive ( 10 fmol) 21 (16) 75 (59) 32 (25) 0.004 (0.06, 0.04)
Unknown 1 (3) 21 (66) 10 (31) —
PgR status
Negative (0–9 fmol) 11 (10) 50 (48) 44 (42) —
Positive ( 10 fmol) 16 (17) 53 (58) 23 (25) 0.009 (0.09, 0.04)
Unknown 1 (2) 33 (67) 15 (31) —
Vessel invasion by primary tumor
No 9 (15) 34 (55) 19 (31) 0.64 (0.24, 0.02)
Yes 19 (10) 102 (55) 63 (34) —
c-erbB-2
Negative 27 (14) 117 (59) 55 (28)  0.001 (0.002,  0.001)
Positive 1 (2) 19 (40) 27 (57) —
Thymidylate synthase
Low 8 (12) 34 (52) 23 (35) —
High 20 (11) 99 (56) 58 (33) 0.90 (0.89, 0.33)
Unknown 0 (0) 3 (75) 1 (25) —
Nottingham type by prognosis category
1. Excellent 6 (86) 0 (0) 1 (14) —
2. Good 16 (36) 28 (62) 1 (2)  0.001 ( 0.001,  0.001)
3. Average 0 (0) 15 (83) 3 (17) —
4. Relatively poor 6 (3) 93 (53) 77 (44) —
ER: estrogen receptor; PgR: progesterone receptor.
a Three P values are presented in the following order: Nottingham/Ki-67 grade P value (Nottingham grade P value, Bloom–Richardson grade P value).
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tive disease (Table 1). The chi-square P values are
shown for the associations of NKG, NHG, and BRG
with the various patient characteristics. Among the
patients with lymph node negative disease, character-
istics that correlated significantly with NKG were BRG,
NHG, pathologic tumor size, and Nottingham type.
Higher NKG tended to be associated with high BRG,
high NHG, tumors  2 cm in greatest dimension, and
tumors that indicated a poor prognosis. A marginally
significant association also was observed between c-
erbB-2 and NKG, with higher grades associated more
often with c-erbB-2 overexpression. Some character-
istics that previously were associated significantly with
or marginally with NHG in patients with lymph node
negative disease, such as ER status and progesterone
receptor (PgR) status, were not correlated with NKG.
In addition, some characteristics that previously were
associated significantly with BRG in these patients,
such as PgR status and vessel invasion, were not cor-
related significantly with NKG.
Among patients with lymph node positive disease,
BRG, NHG, and Nottingham type also were correlated
significantly with NKG. In addition, patients with neg-
ative ER status, negative PgR status, and c-erbB-2
overexpressed tumors were much more likely to have
high NKG. A marginal association was observed be-
tween NKG and pathologic tumor size, with larger
tumors tending to have higher grades. The association
between grade and tumor size was slightly stronger
using the NHG and BRG systems compared with the
NKG system.
The prognostic significance of NKG was studied in
terms of DFS and OS (Figs. 1, 2) in both the lymph
node negative group and the lymph node positive
group. Cox proportional hazards regression models
with a single covariate for NKG were used to estimate
HRs for each treatment group, with a HR  1.0 indi-
cating an increase in risk for each increment in histo-
logic grade (Table 2). Patients with higher grade tu-
mors had significantly worse OS for both the lymph
node negative group and the lymph node positive
group, with the exception of patients with lymph node
negative disease who were on the no PeCT treatment
regimen. In this group, no significant differences in OS
could be detected for the different levels of NKG. An
increase in NKG for patients who had lymph node
positive disease had a more detrimental effect on OS
compared with patients who had lymph node negative
disease. These patterns of association also were ob-
served for DFS, but the statistical significance was
diminished except among patients with lymph node
positive disease who were on prolonged treatment.
The various grading systems performed similarly
in terms of prognostic value for DFS and OS for the
analyses stratified by treatment regimen and lymph
node status. The DFS and OS treatment comparisons
were analyzed separately for patients with NKG 1,
NKG 2, and NKG 3 tumors. Among the patients with
lymph node positive disease who had NHG 3 tumors,
patients who received prolonged treatment had signif-
icantly increased DFS and OS percentages (P  0.007
and P  0.01, respectively) compared with patients
FIGURE 1. Disease free survival (A)
and overall survival (B) for the lymph
node negative cohort according to Not-
tingham/Ki-67 Grade.
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who were given PeCT. This survival advantage was not
expressed among patients with BRG 3 or NKG 3 tu-
mors. However, a significant DFS advantage (P 0.05)
was observed for patients on the prolonged treatment
with NKG 2 tumors that was not suggested under the
other grading strategies. For patients with lymph node
negative disease who had NKG 3 tumors, a nonsignif-
icant DFS and OS disadvantage was seen for women
who received PeCT compared with women who re-
ceived no adjuvant treatment. Among the patients
with node positive disease, it was observed that the
prolonged treatment surpassed the PeCT regimen in
terms of survival and DFS benefits for all levels of NKG
tumors.
Multivariate analyses with NKG fixed in the model
showed that, for patients with lymph node negative
disease who were not on the PeCT treatment, infor-
mation regarding vessel invasion by primary tumor
contributed significantly beyond NKG to the estima-
tion of hazards for OS and DFS. For OS, the HR for an
increase of 1 NKG remained insignificantly different
from 1 (P  0.76; 95%CI, 0.43–1.36), whereas the HR
for presence of vessel invasion by the primary tumor
was 2.30 (P  0.05; 95%CI, 1.01–5.23). Results were
similar but less pronounced for DFS, with the HR for
vessel invasion by the primary tumor becoming 1.95
(P  0.05; 95%CI, 0.99 –3.84). For patients with lymph
node negative disease who received PeCT treatment,
pathologic tumor size contributed information be-
yond NKG in hazard estimation for OS, and PgR status
and vessel invasion contributed further information
for DFS. In patients with node positive disease who
received PeCT treatment, c-erbB-2 expression contrib-
uted significant information beyond NKG regarding
OS prognosis, and vessel invasion contributed further
information for DFS. Among the patients with node
positive disease who were on prolonged treatment,
knowledge of pathologic tumor size and c-erbB-2 ex-
pression, in addition to NKG, made both OS and DFS
more precise.
Categoric Ki-67 as an Independent Parameter
We analyzed the correlation between patient charac-
teristics and the Ki-67 categories for patients with
lymph node negative disease and patients with lymph
node positive disease, respectively. BRG, NHG, and
Nottingham type were correlated significantly with
Ki-67 percentages among both patients with lymph
node negative disease and patients with lymph node
positive disease, in whom it was observed that high
proportions of patients with low-grade tumors had
Ki-67 percentages  9.5%. In the cohort of patients
with lymph node positive disease, tumors that did not
overexpress c-erbB-2 were much more likely to have
low Ki-67 percentages. Pathologically defined grades
were correlated more strongly with pathologic fea-
tures other than Ki-67 both in patients with lymph
node negative disease and in patients with lymph
node positive disease.
An analysis of categoric Ki-67 as an independent
FIGURE 2. Disease free survival (A)
and overall survival (B) for the lymph
node positive cohort according to Not-
tingham/Ki-67 Grade.
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parameter revealed that patients with higher Ki-67
percentages had significantly or marginally worse OS
in both the lymph node negative group and the lymph
node positive group, with the exception of patients in
the lymph node negative group who were on the no-
PeCT treatment regimen, for whom no prognostic
value of Ki-67 was observed. These patterns of asso-
ciation also were observed for DFS with diminished
statistical significance. Treatment regimens were eval-
uated within each of the three Ki-67 categories in this
subset of patients; however, no additional insight was
revealed regarding treatment response or resistance.
DISCUSSION
Numerous studies have shown that morphologic as-
sessment of tumor differentiation provides prognostic
information in patients with breast carcinoma.44 – 46
The concept that the nuclear morphology of tumor
cells may have implications for their biologic behavior
is due to von Hansemann,47 and his studies have been
the starting point for many grading systems for carci-
noma. He considered the mitotic rate in the tumor
and the occurrence of abnormal mitoses as important
characteristics48 and concluded that higher degrees of
anaplasia indicated a greater tendency of the tumor to
metastasize. Salomon49 studied the correlation be-
tween the clinical course of breast carcinoma and the
morphologic alterations and found that the degree of
anaplasia was of prognostic importance. Greenough50
stressed the importance of cytologic changes as well as
histologic changes in tumors, and that method was
modified by Patey and Scarff51 and by Bloom.3
Since those studies were published, several mod-
ifications have been proposed, stressing the fact that
the histologic grading of breast carcinoma is a subjec-
tive evaluation and, inherently lacks reproducibility.
The Bloom–Richardson method was modified7,52 to
make the criteria more objective. The most notable
TABLE 2
Ten-Year Disease Free Survival and Overall Survival According to Nottingham/Ki-67 Grade
Characteristic
No. of
patients
DFS OS
No. of
failures
Ten-yr DFS
 SE (%) HRa 95%CI P valueb
No. of
deaths
Ten-yr OS
 SE (%) HRa 95%CI P valueb
Lymph node negative
Nottingham/Ki-67 grade
Grade 1 33 14 66  8 — — — 8 84  7 — — —
Grade 2 94 54 48  5 1.19 0.90–1.57 0.22 (0.12, 0.34) 36 66  5 1.28 0.91–1.81 0.16 (0.08, 0.05)
Grade 3 61 33 53  6 — — — 24 65  6 — — —
No PeCT
Grade 1 11 6 64  15 — — — 4 82  12 — — —
Grade 2 32 21 44  9 0.88 0.55–1.40 0.59 (0.63, 0.58) 17 56  9 0.76 0.43–1.31 0.32 (0.70, 0.58)
Grade 3 20 9 69  11 — — — 4 80  9 — — —
PeCTc
Grade 1 22 8 67  10 — — — 4 86  8 — — —
Grade 2 62 33 50  7 1.40 0.98–1.99 0.07 (0.03, 0.41) 19 72  6 1.77 1.12–2.79 0.01 (0.02, 0.03)
Grade 3 41 24 46  8 — — — 20 58  8 — — —
Lymph node positive
Nottingham/Ki-67 grade
Grade 1 28 13 64  9 — — — 10 78  8 — — —
Grade 2 136 96 33  4 1.55 1.21–1.98  0.001 (0.005,  0.001) 73 51  4 1.81 1.37–2.39  0.001 ( 0.002,  0.001)
Grade 3 82 59 27  5 — — — 56 31  5 — — —
PeCTc
Grade 1 9 6 42  17 — — — 4 76  15 — — —
Grade 2 48 39 23  6 1.39 0.94–2.04 0.10 (0.01, 0.02) 28 48  7 1.88 1.20–2.93 0.005 (0.002, 0.004)
Grade 3 32 24 22  8 — — — 24 21  8 — — —
Prolonged treatment
Grade 1 19 7 74  10 — — — 6 79  9 — — —
Grade 2 88 57 39  5 1.64 1.20–2.25 0.002 (0.09,  0.001) 45 53  5 1.74 1.22–2.47 0.002 (0.12, 0.001)
Grade 3 50 35 29  7 — — — 32 37  7 — — —
DFS: disease free survival; SE: standard error; HR: hazard ratio; 95%CI: 95% confidence interval; OS: overall survival; PeCT: perioperative chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil.
a The HR is shown for an increase of 1 grade level.
b Three P values are presented in the following order: Nottingham/Ki-67 grade P value (Nottingham grade P value, Bloom–Richardson grade P value).
c A single course of combination intravenous PeCT was given on Days 1 and 8 and commencing within 36 hours of mastectomy.
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improvement was the assignment of points for mitotic
counts according to high-power field area for each of
three types of microscopes. The authors claimed that,
if the grading protocol was followed consistently, then
reproducible results could be obtained. A subsequent
study53 showed that the Nottingham modification of
the BRG system was a suitable scheme for evaluating
invasive ductal breast carcinomas in the routine, clin-
ical setting.
The rate at which a tumor proliferates has long
been correlated with its clinical course. Histopatholo-
gists, therefore, have sought a means of determining
the rate of tumor proliferation as an adjunct to diag-
nosis. The simplest and most established of these
practices is a count of mitotic figures. Other well-
established techniques for accurately measuring the
growth rate of tumors include tritiated thymidine,54
bromodeoxyuridine incorporation,55 and flow cytom-
etry.56 The use of antibodies to Ki-67 is a reliable and
easy means of accurately assessing the growth fraction
of human neoplasms. An almost perfect correlation
has been demonstrated between visual counting tech-
niques and image analyzing systems in the determi-
nation of the percentage of cells stained with Ki-67.57
The growth fraction of tumors now can be as-
sessed on paraffin sections of tissues using the mono-
clonal antibody MIB-1 using a microwave antigen-
retrieval technique. This antibody appears to be
superior to others for assessing tumor proliferation on
routinely fixed and processed material, not only be-
cause of the simplicity of the technique but because
good correlation with Ki-67 expression on frozen ma-
terial also has been reported.
In patients with breast carcinoma, although some
authors have found no association between Ki-67 im-
munoreactivity and other prognostic variables,58
many authors have reported an association with his-
tologic grade,59 – 61 lymph node status,61 patient age,62
tumor size,61,63 ER and PgR status,61,63– 65 ploidy,66 p53
status,67 and epidermal growth factor receptor expres-
sion.68 An association between Ki-67 staining and
both disease free interval and survival has been re-
ported.69 However, few studies have assessed the per-
centage of tumor cells that expressed the Ki-67 antigen
in patients with long-term follow-up because of the
difficulty in obtaining sufficient archival frozen tissue.
The current study is the first to assess the Ki-67
immunoreactivity and compare the Ki-67 index with
the Bloom–Richardson and Nottingham grading sys-
tems in a large series of well-characterized patients
with lymph node negative disease and patients with
lymph node positive disease who underwent specific
therapeutic regimens with long-term follow-up data
available. Ki-67 expression was studied in categoric
form and by substituting the mitotic counts-morpho-
logic feature in the Nottingham criteria, resulting in
the Nottingham/Ki-67 grading system. The NKG was
correlated highly with tumor grade and tumor size in
patients with lymph node negative disease and with
tumor grade, hormone receptor status, and c-erbB-2
expression in patients with lymph node positive dis-
ease. In both patients with lymph node negative dis-
ease and patients with lymph node positive disease,
the agreement between NKG, NHG, and BRG was
high, with the agreement between any two grading
systems significantly higher compared with chance
alone (P  0.001). The prognostic value of all three
grading systems for survival and DFS, stratified by
treatment regimen and lymph node status, was simi-
lar. The study confirms the value of Ki-67 evaluation
as an objective means for the prediction of histologic
grade and survival in patients with breast carcinoma.
It is not suggested that measurement of Ki-67 alone
can provide data of equivalent value to grading. What
is demonstrated is that Ki-67 is a very reliable replace-
ment for mitotic counts and would be easier to apply
in FNAs and core biopsies, in which there are limited
numbers of cells present.
We also conducted analyses to investigate the
magnitude of treatment effects within subgroups de-
fined by grade. Although various associations between
grade, as assessed by the different systems and treat-
ment effects, were identified, these should be inter-
preted as exploratory given the retrospective nature of
the subgroup analyses. Multivariate analyses indi-
cated that factors such as vessel invasion, pathologic
tumor size, steroid hormone receptor status, and c-
erbB-2 expression contributed prognostic information
in addition to grade.
Although tumor grade by itself is not sufficient to
define prognosis optimally for any subgroup exam-
ined, other features may not be assessed as easily as
the use of neoadjuvant chemotherapy increases. Fur-
thermore, as more conservative surgical and staging
techniques increasingly are introduced into the man-
agement of patients with breast carcinoma, much use-
ful prognostic information, including tumor size, tu-
mor grading, vascular invasion, and lymph node
involvement, will not be assessable.
Therefore, new markers that can be applied to
small samples and that may be of prognostic signifi-
cance will be invaluable. One obvious approach would
be to use ER as a surrogate of differentiation (tubules
in Nottingham grading) and p53 overexpression as a
surrogate of nuclear pleomorphism. There are many
other possible parameters to assess, but there is a
need for a large, controlled study to assess markers in
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small biopsies and FNAs that can substitute for the
parameters used in classic grading.
Ki-67-related antigen can be determined easily
using immunohistochemistry in tumor samples ob-
tained by multiple needle core biopsies and in cyto-
logic specimens, both before and after treatment. In
conclusion, Ki-67 detection represents a valuable tool
that, in combination with other clinical, pathologic,
and biologic parameters, should be analyzed further
to produce a grading system that can be applied re-
producibly to small tissue samples.
REFERENCES
1. Bloom HJG, Richardson WW. Histologic grading and prog-
nosis in breast cancer: a study of 1409 cases of which 359
have been followed for 15 years. Br J Cancer. 1957;11:359 –
377.
2. Patey DH, Scarff RW. The position of histology in the prog-
nosis of carcinoma of the breast. Lancet. 1928;1:801– 804.
3. Bloom HJG. Prognosis in carcinoma of the breast. Br J Can-
cer. 1950;4:259 –288.
4. Bloom HJG. Further studies on prognosis of breast carci-
noma. Br J Cancer. 1950;4:347–367.
5. Black MM, Barclay THC, Hankey BF. Prognosis in breast
cancer utilizing histologic characteristics of the primary tu-
mor. Cancer. 1975;36:2048 –2055.
6. Gusterson BA. Prognostic variables and future predictors of
behavior and response. Recent results in cancer and re-
search, vol 140. Berlin: Springer-Verlag, 1996.
7. Elston CW, Ellis IO. Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer:
experience from a large study with long-term follow up.
Histopathology. 1991;19:403– 410.
8. Page DL, Ellis IO, Elston CW. Histologic grading of breast
cancer. Let’s do it. Am J Clin Pathol. 1995;103:123–124.
9. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston
CW. Pathological prognostic factors in breast cancer. II.
Histological type. Relationship with survival in a large study
with long-term follow-up. Histopathology. 1992;20:479 – 489.
10. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative
chemotherapy on the outcome of women with operable
breast cancer. J Clin Oncol. 1998;16:2672–2685.
11. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of
chemoendocrine therapy started before or after surgery for
treatment of primary breast cancer. J Clin Oncol. 1995;13:
547–552.
12. Eisen T, Smith IE, Johnson S, et al. Randomized Phase II trial
of infusional fluorouracil, epirubicin and cyclophosphamide
versus infusional fluorouracil, epirubicin and cisplatin in
patients with advanced breast cancer. J Clin Oncol. 1998;16:
1350 –1357.
13. Powles TJ. Adjuvant therapy for early breast cancer: a time
to refine. J Natl Cancer Inst. 1997;89:1652–1654.
14. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node
biopsy to avoid axillary dissection in breast cancer with clini-
cally negative lymph nodes. Lancet. 1997;349:1864–1867.
15. Haffty BG, Ward B, Pathare P. Reappraisal of the role of
axillary lymph node dissection in the conservative treatment
of breast cancer. J Clin Oncol. 1997;15:691–700.
16. Davis BW, Gelber RD, Goldhirsch A, et al. Prognostic signif-
icance of peritumoral vessel invasion in clinical trials of
adjuvant therapy for breast cancer with axillary lymph node
metastasis. Hum Pathol. 1985;16:1212–1218.
17. Seidman JD, Schnaper LA, Aisner SC. Relationship of the
size of the invasive component of the primary breast carci-
noma to axillary lymph node metastasis. Cancer. 1995;75:
65–71.
18. Cady B, Stone M, Schuler JG, Thakur R, Wanner MA, Larin
PT. The new era in breast cancer. Invasion, size and nodal
involvement dramatically decreasing as a result of mam-
mography screening. Arch Surg. 1996;131:301–308.
19. Makris A, Allred DC, Powles TJ, et al. Cytological evaluation
of biological prognostic markers from primary breast carci-
nomas. Breast Cancer Res Treat. 1997;44:65–74.
20. Hall PA, Levison DA. Review: assessment of cell proliferation
in histological material. J Clin Pathol. 1990;43:184 –192.
21. Hall PA, Levison DA, Wright NA. Assessment of cell prolif-
eration in clinical practice. Berlin: Springer Verlag, 1992.
22. Galand P, Degraef C. Cyclin/PCNA immunostaining as an
alternative to tritiated thymidiline pulse labeling for mark-
ing S phase cells in paraffin sections from animal and hu-
man tissues. Cell Tissue Kinet. 1989;22:383–392.
23. Scott RJ, Hall PA, Haldane JS, et al. A comparison of immu-
nohistochemical markers of cell proliferating with experi-
mentally determined growth fraction. J Pathol. 1991;165:
173–178.
24. Gerdes J, Schwab U, Lemke H, Stein H. Production of a
mouse monoclonal antibody reactive with a human nuclear
antigen associated with cell proliferation. Int J Cancer. 1983;
31:13–20.
25. Gerdes J, Lemke H, Baisch H, Walker H, Schwab U, Stein H.
Cell cycle analysis of a cell proliferation associated human
nuclear antigen defined by the monoclonal antibody Ki-67.
J Immunol. 1984;133:1710 –1715.
26. Dalquen P, Baschiera B, Chaffard R, et al. MIB-1(Ki-67)
immunostaining of breast cancer cells in cytologic smears.
Acta Cytol. 1997;41:229 –237.
27. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibod-
ies against recombinant parts of the Ki-67 antigen (MIB1
and MIB3) detect proliferating cells in microwave-processed
formalin-fixed, paraffin sections. J Pathol. 1992;168:357–363.
28. Walker RA, Camplejohn RS. Comparison of monoclonal an-
tibody Ki-67 reactivity with grade and DNA flow cytometry
of breast carcinomas. Br J Cancer. 1988;57:281–283.
29. Dawson AE, Norton JA, Weinberg DS. Comparative assess-
ment of proliferation and DNA content in breast carcinoma
by image analysis and flow cytometry. Am J Pathol. 1990;
136:1115–1124.
30. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of
cell proliferation in breast carcinoma. Comparison of Ki-67
immunohistochemical study: DNA flow cytometric analysis,
and mitotic count. Cancer. 1990;65:1180 –1184.
31. Sasaki K, Matsumura T, Tsujj T, Shinozaki F, Takahaski M.
Relationship between labeling indices of Ki-67 and BrdUrd
in human malignant tumors. Cancer. 1988;62:989 –993.
32. McCormick D, Yu C, Hobbs C, Hall PA. The relevance of
antibody concentration to the immunohistological quanti-
fication of cell proliferation-associated antigens. Histopa-
thology. 1993;22:543–547.
33. Ludwig Breast Cancer Study Group. Combination adjuvant
chemotherapy for node-positive breast cancer: inadequacy
of a single perioperative cycle. N Engl J Med. 1988;319:677–
683.
1330 CANCER March 1, 2003 / Volume 97 / Number 5
34. Ludwig Breast Cancer Study Group. Prolonged disease-free
survival after one course of perioperative adjuvant chemo-
therapy for node-negative breast cancer. N Engl J Med.
1989;320:491– 496.
35. Goldhirsch A, Gelber RD, Castiglione M, et al., for the Inter-
national Breast Cancer Study Group. Present and future
projects of the International Breast Cancer Study Group.
Cancer. 1994;3(Suppl):1139 –1149.
36. Gusterson BA, Gelber RD, Goldhirsch A, et al., for the Inter-
national Breast Cancer Study Group. Prognostic importance
of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;
10:1049 –1056.
37. Gusterson BA, Gelber RD, Goldhirsch A, et al., for the Inter-
national Breast Cancer Study Group. Prognostic importance
of c-erbB-2 expression in breast cancer. J Clin Oncol/Classic
Papers Current Comments. 2001;5:908 –916.
38. Pestalozzi BC, Peterson HF, Gelber RD, et al. The prognostic
importance of thymidylate synthase expression in early
breast cancer. J Clin Oncol. 1997;15:1923–1931.
39. Pinder SE, Murray S, Ellis IO, et al. The importance of
histological grade in invasive breast carcinoma and re-
sponse to chemotherapy. Cancer. 1998;83:1529 –1539.
40. Cohen J. Weighted kappa: nominal scale agreement with
provision for scaled disagreement or partial credit. Psychol
Bull. 1968;70:213–220.
41. Pearson, K. On the criterion that a given system of devia-
tions from the probable in the case of a correlated system of
variables is such that it can be reasonably supposed to have
arisen from random sampling (series 5). Philosophical Mag-
azine. 1900;50:157–175.
42. Cox DR. Regression models and life-tables (with discussion).
J R Stat Soc B (Methodol). 1972;34:187–220.
43. Kaplan EL, Meier P. Nonparametric estimation from incom-
plete observations. J Am Stat Assoc. 1958;53:457– 481.
44. Davis BW, Gelber RD, Goldhirsh A, et al. Prognostic signif-
icance of tumor grade in clinical trials of adjuvant therapy
for breast cancer with axillary lymph node metastasis. Can-
cer. 1986;58:2662–2670.
45. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D,
Rouesse J. The importance of histologic grade in long-term
prognosis of breast cancer: a study of 1010 patients, uni-
formly treated at the Institute Gustave-Roussy. J Clin Oncol.
1987;5:1378 –1386.
46. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K,
Spyratos F, Brunet M. Prognostic value of histologic grade
nuclear components of Scarff–Bloom–Richardson (SBR): an
improved score modification based on a multivariate anal-
ysis of 1262 invasive ductal breast carcinomas. Cancer. 1989;
64:1914 –1921.
47. von Hansemann D. Ueber assymetrische Zelltheilung in
Epithelkrebsen und deren biologische Beteudung. Virchows
Arch Pathol Anat. 1890;119:299 –326.
48. von Hansemann D. Ueber die Anaplasie der Geschwulst-
zellen und die asymmetrische mitose. Virchows Arch Pathol
Anat. 1892;129:436 – 449.
49. Salomon A. Beitrage zur Pathologie und Klinik der Mam-
macarcinome. Arch Klinischen Chirurgie. 1913;101:573– 668.
50. Greenough RB. Varying degrees of malignancy in cancer of
the breast. J Cancer Res. 1925;9:453– 463.
51. Patey DH, Scarff RW. The position of histology in the prog-
nosis of carcinoma of the breast. Lancet. 1928;1:801– 804.
52. Elston CW. The assessment of histological differentiation in
breast cancer. Aust NZ J Surg. 1984;54:11–15.
53. Frierson HF, Wolber RA, Berfan KW, et al. Interobserver
reproducibility of the Nottingham modification of the
Bloom and Richardson histologic grading scheme for infil-
trating ductal carcinoma. Am J Clin Pathol. 1995;103:195–
198.
54. Malaise EP, Chavaudra N, Tubiana M. The relationship be-
tween growth rate, labelling index and histological type of
human solid tumors. Eur J Cancer. 1973;9:305–312.
55. Dean PN, Dolbeare F, Gratzner H, Rice GC, Gray JW. Cell-
cycle analysis using a monoclonal antibody to BrdUrd. Cell
Tissue Kinet. 1984;17:427– 436.
56. Quirke P, Dyson JED. Flow cytometry: methodology and
applications in pathology. J Pathol. 1986;149:79 – 87.
57. Franklin WA, Bibbo M, Doria MI, et al. Quantitation of
estrogen receptor content and Ki-67 staining in breast car-
cinoma by the micro-TICAS image analysis system. Anal
Quant Cytol Histol. 1987;9:279 –283.
58. Stumpp J, Dietl J, Geppert M. Growth fraction in breast
carcinoma determined by Ki-67 immunostaining: correla-
tion with pathological and clinical variables. Gynaecol Ob-
stet Invest. 1992;33:47–50.
59. Betta PG, Robutti F, Pilato FP, Spiroglio G, Bottero G. Cor-
relation of proliferation activity with pathological features in
breast carcinoma. Eur J Gynaecol Oncol. 1989;10:433– 437.
60. Bouzubar N, Walker KJ, Griffiths K, et al. Ki-67 immuno-
staining in primary breast cancer: pathological and clinical
associations. Br J Cancer. 1989;59:943–947.
61. Wrba F, Chott A, Reiner A, Markis-Ritzinger EM, Holtzner
JH. Ki-67 immunoreactivity in breast carcinomas in relation
to transferrin receptor expression, estrogen receptor status
and morphological criteria. An immunohistochemical
study. Oncology. 1989;46:255–259.
62. Sahin AA, Ro JY, Block MB, et al. Ki-67 immunostaining in
node-negative Stage I/II breast carcinoma. Significant cor-
relation with prognosis. Cancer. 1991;68:549 –557.
63. Veronese SM, Gambacorta M. Detection of Ki-67 prolifera-
tion rate in breast cancer. Correlation with clinical and
pathologic features. Am J Clin Pathol. 1991;95:30 –34.
64. Campani D, De-Negri F, Fabri R, et al. Estrogen, progester-
one receptors and proliferating activity evaluated by immu-
nocytochemistry in breast cancer. Int J Biol Markers. 1991;
6:144 –150.
65. Di-Stefano D, Mingazzini PL, Scucchi L, Donnetti M, Mari-
nozzi V. A comparative study of histopathology, hormone
receptors, peanut lectin binding, Ki-67 immunostaining,
and nucleolar organizer region-associated proteins in hu-
man breast cancer. Cancer. 1991:67;463– 471.
66. Lee AK, Wiley B, Loda M, et al. DNA ploidy, proliferation and
neu-oncogene protein overexpression in breast carcinoma.
Mod Pathol. 1992;5:61– 67.
67. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma O. p53
and c-erbB-2 protein expression in breast carcinomas. An
immunohistochemical study including correlation with re-
ceptor status, proliferating markers, and clinical stage in
human breast cancer. Am J Clin Pathol. 1992;98:408 – 418.
68. Nicholson RI, McClelland RA, Finlay P, et al. Relationship
between EGF-R, c-erbB-2 protein expression and Ki-67 im-
munostaining in breast cancer and hormone sensitivity. Br J
Cancer. 1993;29A:1018 –1023.
69. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari
M, Lambertico P. Proliferation index as a prognostic marker
in breast cancer. Cancer. 1993;71:3926 –3931.
Ki-67 Expression in Breast Carcinoma/Trihia et al. 1331
